2016
Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy
Srivastava KD, Siefert A, Fahmy TM, Caplan MJ, Li XM, Sampson HA. Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy. Journal Of Allergy And Clinical Immunology 2016, 138: 536-543.e4. PMID: 27130858, DOI: 10.1016/j.jaci.2016.01.047.Peer-Reviewed Original ResearchConceptsPeanut oral immunotherapyOral peanut challengesPeanut-specific immunotherapyPeanut allergyOral immunotherapyPeanut challengeSymptom scoresRecall responsesMurine modelSplenocyte culturesHistamine levelsPeanut-specific serum IgEC3H/HeJ miceIFN-γ levelsPlasma histamine levelsVehicle control animalsCytokine recall responsesLower symptom scoresBody temperatureCurrent clinical approachesOral sensitizationWeekly gavageIgG2a levelsSublingual immunotherapySerum IgE
2015
Investigation of Peanut Oral Immunotherapy Using CpG/Peanut-Nanoparticles in a Murine Model of Peanut Allergy
Srivastava K, Siefert A, Fahmy T, Caplan M, Li X, Sampson H. Investigation of Peanut Oral Immunotherapy Using CpG/Peanut-Nanoparticles in a Murine Model of Peanut Allergy. Journal Of Allergy And Clinical Immunology 2015, 135: ab235. DOI: 10.1016/j.jaci.2014.12.1701.Peer-Reviewed Original ResearchPeanut allergyMurine model
2009
Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy
Demento SL, Eisenbarth SC, Foellmer HG, Platt C, Caplan MJ, Saltzman W, Mellman I, Ledizet M, Fikrig E, Flavell RA, Fahmy TM. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 2009, 27: 3013-3021. PMID: 19428913, PMCID: PMC2695996, DOI: 10.1016/j.vaccine.2009.03.034.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAnimalsAntibody FormationCarrier ProteinsCD8-Positive T-LymphocytesDendritic CellsLactic AcidLipopolysaccharidesMiceMice, Inbred C57BLNanoparticlesNLR Family, Pyrin Domain-Containing 3 ProteinPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerVaccinationViral Envelope ProteinsWest Nile FeverWest Nile Virus VaccinesConceptsPattern recognition receptorsToll-like receptorsInflammasome activationInnate immune system activationEffective adaptive immune responseIntracellular pattern recognition receptorsAntigen-presenting cellsAdaptive immune responsesWest Nile encephalitisImmune system activationInnate immune pathwaysWild-type macrophagesDendritic cellsCellular immunityVaccination approachesVaccine efficacyIL-1betaNLRP3 inflammasomeAdjuvant systemImmune responsePotent new approachMurine modelInflammasome activitySystem activationImmune pathwaysInflammasome-activating biodegradable nanoparticulates as vaccine delivery systems (135.80)
Fahmy T, DEMENTO S, Eisenbarth S, Caplan M, Saltzman W, Mellman I, Ledizet M, Fikrig E, Flavell R. Inflammasome-activating biodegradable nanoparticulates as vaccine delivery systems (135.80). The Journal Of Immunology 2009, 182: 135.80-135.80. DOI: 10.4049/jimmunol.182.supp.135.80.Peer-Reviewed Original ResearchToll-like receptorsIL-1βInflammasome activationProinflammatory cytokines IL-1βAntigen-presenting cellsClass of nanomaterialsCytokines IL-1βSurface of nanoparticlesWest Nile encephalitisInnate immune pathwaysVaccine delivery systemWild-type macrophagesCellular immunityVaccination approachesMurine modelInflammasome activityType macrophagesImmune pathwaysAdjuvant deliveryDanger signalsVaccine designModel antigenLipopolysaccharideAntigenBiocompatible polyester